Nurix Therapeutics (NASDAQ:NRIX) Now Covered by Analysts at UBS Group

UBS Group initiated coverage on shares of Nurix Therapeutics (NASDAQ:NRIX) in a report issued on Thursday, MarketBeat.com reports. The brokerage issued a buy rating and a $35.00 price objective on the stock.

Several other research firms have also recently weighed in on NRIX. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Nurix Therapeutics in a research report on Monday. Truist Financial began coverage on shares of Nurix Therapeutics in a report on Wednesday, July 31st. They set a “buy” rating and a $36.00 price target for the company. Royal Bank of Canada lowered their price objective on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. JPMorgan Chase & Co. increased their target price on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. Finally, Oppenheimer upped their target price on Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.40.

Nurix Therapeutics Stock Up 1.8 %

Shares of NASDAQ:NRIX opened at $25.22 on Thursday. Nurix Therapeutics has a 12-month low of $4.22 and a 12-month high of $26.43. The company’s 50 day moving average price is $24.01 and its two-hundred day moving average price is $19.88. The firm has a market cap of $1.79 billion, a PE ratio of -8.67 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.67). The business had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. On average, research analysts expect that Nurix Therapeutics will post -2.84 EPS for the current year.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, insider Christine Ring sold 3,290 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $25.00, for a total transaction of $82,250.00. Following the completion of the sale, the insider now directly owns 24,592 shares of the company’s stock, valued at approximately $614,800. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Gwenn Hansen sold 3,408 shares of the stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $70,443.36. Following the completion of the sale, the insider now directly owns 45,150 shares of the company’s stock, valued at approximately $933,250.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Christine Ring sold 3,290 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $25.00, for a total value of $82,250.00. Following the completion of the transaction, the insider now directly owns 24,592 shares in the company, valued at approximately $614,800. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 63,105 shares of company stock valued at $1,507,181 over the last three months. Corporate insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On Nurix Therapeutics

Large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Nurix Therapeutics by 77.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,388 shares of the company’s stock worth $278,000 after buying an additional 5,419 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after acquiring an additional 559 shares during the period. International Assets Investment Management LLC boosted its stake in Nurix Therapeutics by 1,098.4% in the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after acquiring an additional 4,119 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Nurix Therapeutics during the 3rd quarter valued at approximately $3,152,000. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Nurix Therapeutics during the 2nd quarter worth approximately $578,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.